Brain Wealthy
    What's Hot

    Cullman Regional welcomes Kenneth Murray, MD, neurologist and sleep medicine expert.

    February 2, 2023

    Bill Focuses on Mental Health, Wellness Resources for Colorado Students

    February 2, 2023

    Leonard Nimoy Once Explained Huge Competitiveness And Anxiety On The Set Of Star Trek

    February 2, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      Leonard Nimoy Once Explained Huge Competitiveness And Anxiety On The Set Of Star Trek

      February 2, 2023

      Therapist Hong Kong News – Counseling and therapy practice treats post-corona depression anxiety and stress Hong Kong

      February 1, 2023

      Pokemon Scarlet & Violet players fail ‘anxiety-inducing’ shiny encounters due to jump glitch

      February 1, 2023

      Can Mindfulness Soothe Anxiety? The trial suggests yes. – Harvard Gazette

      February 1, 2023

      Best CBD for dog anxiety

      February 1, 2023
    • Emotion

      Humvee details wave of emotions since Ace to Sparks trade

      February 2, 2023

      Stephen ‘tWitch’ Boss’ mother shares emotional reaction to seeing his Gap campaign: ‘I almost called you’

      February 1, 2023

      ‘It’s like, really emotional’: Quakertown students Q&A with Super Bowl-bound Eagles player | Southeast Pennsylvania

      February 1, 2023

      Delight in Cafes: Tweets Reveal Where People Express Different Emotions in a City

      February 1, 2023

      Want to be happier?Millions of Tweets Show Your Location May Affect Your Emotions

      February 1, 2023
    • Neurology

      Cullman Regional welcomes Kenneth Murray, MD, neurologist and sleep medicine expert.

      February 2, 2023

      Repairing cerebrospinal fluid leaks may improve symptoms

      February 1, 2023

      Fear of Public Places Associated with Poor Quality of Life in Adults with Epilepsy

      February 1, 2023

      Novartis discontinues Huntington’s disease program after Phase 2b trial

      February 1, 2023

      Postmenopausal stroke risk dates back to women’s reproductive age

      February 1, 2023
    • Sleep

      What Happens During Your Sleep Cycle?

      February 2, 2023

      Centrepoint will try to sleep out this February.

      February 1, 2023

      Experience America’s Favorite Mattress Tempur-Pedic With The Best Mattress Sleep Specialists – St. George News

      February 1, 2023

      Simple remedies for a good night’s sleep

      February 1, 2023

      Joe Pera launches ‘Drift Off’ podcast to help us fall asleep (again)

      February 1, 2023
    • Brain Research

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023

      Actionable Strategy Report on Brain-Inspired Computing Market

      February 1, 2023

      Disparities associated with differences in brain structure among US children

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Bill Focuses on Mental Health, Wellness Resources for Colorado Students

      February 2, 2023

      Klamath County mental health treatment beds to double in planned expansion

      February 1, 2023

      WIU Introduces Mental Health Awareness Organization to Campus

      February 1, 2023

      Windsor Spitfires Partners with CMHA Windsor-Essex to Host Mental Health Awareness Game

      February 1, 2023

      Bill Focuses on Mental Health, Wellness Resources for Colorado Students

      February 2, 2023

      Klamath County mental health treatment beds to double in planned expansion

      February 1, 2023

      WIU Introduces Mental Health Awareness Organization to Campus

      February 1, 2023

      Windsor Spitfires Partners with CMHA Windsor-Essex to Host Mental Health Awareness Game

      February 1, 2023
    Brain Wealthy
    Home»Neurology»AffaMed Therapeutics Commercializes Galcanezumab for Migraine Prevention in Mainland China
    Neurology

    AffaMed Therapeutics Commercializes Galcanezumab for Migraine Prevention in Mainland China

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 17, 2023No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    affirm get sole commercialization Rights Under Regulatory Approvals Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). It aims to address the unmet medical needs of millions of migraine sufferers in China.

    Shanghai, January 17, 2023 /PRNewswire/ — AffaMed Therapeutics (“AffaMed”) today announced that it is a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet medical needs in neurological, psychiatric and ocular diseases. and Eli Lilly and Company (“Eli Lilly”) intends to acquire the exclusive commercialization rights to import, market, promote, distribute and refine galcanezumab after approval in mainland China. increase. Lilly has submitted a new drug application for galcanezumab for the prophylaxis and treatment of episodic migraines in adults in the United States. Chinese National Medical Products Administration (“NMPA”) June 2022.

    Migraine is a disabling neurological disease that affects nearly 1 in 10 Chinese and an estimated 130 million patients, approximately two-thirds of whom are women.[1]Despite its high prevalence, migraine remains underrecognized and undertreated. ChinaBased on years of scientific and commercial experience and insights in the Chinese migraine market, AffaMed has established this partnership with Eli Lilly to address a critical unmet need and improve quality of life for migraine sufferers. view it as an important opportunity to improve. China.

    “We are thrilled to have reached an agreement with Eli Lilly to bring this innovative product to Chinese patients suffering from migraine headaches, a condition that dramatically impairs their quality of life.” Zhao TaoyoAffaMed’s CEO commented:

    In Phase 3 PERSIST[2]A study, randomized, double-blind, placebo-controlled pivotal trial was designed to evaluate the efficacy and safety of galcanezumab in patients with episodic migraine from . China, IndiaWhen Russia, the least-squares (LS) mean reduction from baseline in monthly MHD over 3 months was significantly greater with galcanezumab compared with placebo (-3.81 days vs. -1.99 days; p < 0.0001). A significantly higher mean proportion of patients in the galcanezumab and placebo groups decreased MHD from baseline by ≥50%, ≥75% and 100% (all p < 0.0001).

    About migraines

    Migraine is a severe, disabling neurological disorder characterized by recurrent episodes of moderate to severe headache accompanied by other symptoms such as nausea, sensitivity to light and sensitivity to sound.[3],[4] The prevalence in Chinese is 9.3%, while the prevalence in women is 12.8%, more than double the prevalence in men of 5.8%.[1] It is reported to be the second most disabling disease affecting daily life of all diseases.[5]

    About galcanezumab

    Galcanezumab is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Developed by Eli Lilly and approved by the FDA. September 2018 Prophylactic treatment of migraine in adults, and June 2019 For the treatment of episodic cluster headaches in adults. Galcanezumab (under the brand name Emgality® usa) is an innovative therapeutic approach to this neurological disorder and is also the first and only drug approved by the US FDA to reduce the number of attacks for the treatment of episodic cluster headache. It is currently used by migraine sufferers in 20 countries around the world.

    About AffaMed Therapeutics

    AffaMed Therapeutics is a clinical-stage biopharmaceutical company with innovative pharmaceutical, digital and surgical products that address significant unmet medical needs in ophthalmic, neurological and psychiatric disorders in ophthalmic, neurological and psychiatric patients focused on the development and commercialization of Greater China and around the world. AffaMed Therapeutics’ management team has acquired deep industry expertise and extensive experience in high-quality discovery, clinical development, regulatory affairs, business development, manufacturing, and commercial operations with leading multinational biopharmaceutical companies. I’m here. China and globally.

    Disclaimer

    The product mentioned is currently an investigational drug for the indicated indication and is not yet approved in mainland China. Affamed and Lilly do not endorse the use of unapproved medicines or indications.

    References

    [1]Yu S, Liu R, Zhao G, et al. Prevalence and Burden of Primary Headache in China: A Population-Based Visitor Survey. headache. 2012, 52:582-591.

    [2]Hu et al. Phase 3, Randomized, Double-Blind, Placebo-Controlled PERSIST Study, The Journal of Headache and Pain. 2022

    [3]Katsarava Z, Buse D, Manack A, et al. Definition of the difference between episodic and chronic migraine. Current pain headache report. 2012; 16:86.

    [4]Blumenfeld AM, Payne KA, Varon SF, et al. Disability, HRQOL, and resource use in patients with chronic and episodic migraine. Results from the International Burden of Migraine Study (IBMS). headache. 2011;31:301.

    [5]GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis of the 2016 Global Burden of Disease Study. Lancet Neurol 17(11):954. –76

    Source AffaMed Therapeutics Ltd.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleObserving the Sabers: Panthers loss premature emotional disappointment for Buffalo
    Next Article IBRO/IBE-UNESCO Science of Learning Fellowships 2023 (up to €20,000)
    brainwealthy_vws1ex
    • Website

    Related Posts

    Cullman Regional welcomes Kenneth Murray, MD, neurologist and sleep medicine expert.

    February 2, 2023

    Repairing cerebrospinal fluid leaks may improve symptoms

    February 1, 2023

    Fear of Public Places Associated with Poor Quality of Life in Adults with Epilepsy

    February 1, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.